PainReform Ltd. announced it has reached the 50% enrollment target for the second part of Phase 3 clinical trial of PRF-110 in bunionectomy. In total, over 200 patients have been enrolled, of up to approximately 400 patients at eight clinical sites across the U.S.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8455 USD | +5.67% | +8.40% | -69.25% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-69.25% | 2.09M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- PRFX Stock
- News PainReform Ltd.
- PainReform Ltd. Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy